sector medic suppli devic
messag report solid result revenu ep beat
guidanc nudg higher sale top consensu led
strong perform omnipod elsewher updat coverag
eu transit manufactur dash horizon gener posit
solid near-term momentum much look forward
continu view well posit continu out-performance pt move
due recent peer group multipl compress reiter
strong omnipod sale account major upsid omnipod
revenu rose beat consensu new patient start remain
strong come record quarterli level fourth straight quarter meanwhil
intern omnipod sale ahead street cc
transit direct european sale forc continu pay dividend final drug
deliveri sale buck recent trend increas
street expect despit posit surpris remain cautiou segment
given challeng long-term trajectori neulasta face gener competit
concern reflect manag guidanc piec busi still
call revenu declin yoy
momentum core omnipod busi remain strong estim
world-wide custom base grew yoy patient growth domest
increas ou broader payer coverag easier access
pharmaci channel drive adopt transit direct sale forc
intern continu drive gain go forward also benefit
recent progress made payer dash cover live
vs exit expect full roll-out dash mobil platform
gener signific buzz among patient dash launch also add increment layer
complex outlook lower up-front revenu new patient start
made time higher pod dynam expect
result headwind revenu full year manag estim
fulli off-set higher omnipod revenu per patient net benefit
longer term
guidanc move slightli higher manag updat guidanc call total revenu
vs previou rang omnipod sale
expect come intern revenu forecast
compar previou rang
respect final drug deliveri sale project
vs previous begin feel impact gener competit
meanwhil regulatori timelin horizon ap program unchang
manag still target fda approv somewhat late
game first close loop offer think horizon potenti win
patient given simplic patch pump form factor novel featur like direct
smartphon control meanwhil recent complet studi evalu use
omnipod concentr insulin expect submit fda next
week put track fda approv yearend increas
compani appeal type patient compat formul expect
seen bigger opportun
page analyst certif import disclosur
elsewher continu support tidepool develop open-sourc
ios-bas loop app algorithm use omnipod eventu
horizon program compani promot current off-label use loop
technolog believ activ do-it-yourself pumper commun indic
signific market demand improv glucos control solut interest
combin loop algorithm omnipod particular bode well adopt
formal collabor eventu result fda approv meanwhil clinic
perspect showcas new data next month ada includ abstract
report posit outcom horizon improv time-in-rang glycem control
use preschool children age well real-world long-term data
incom statement strong gross margin allow top line beat
flow earn report gross margin yoy
consensu progress front expect limit
new manufactur facil ramp product longer term howev
manag remain confid goal hit gm elsewher sg
expens rose yoy sale street estim
leverag off-set spend howev rose yoy revenu
consensu combin drove oper margin vs
street forecast ep came consensu
solid momentum kick reiter buy model call post
ep total revenu cc compar prior
forecast respect longer term confid abil
sustain top line growth trajectori unchang howev
lower price target previous base
previous multipl forward ntm revenu estim valuat
upsid potenti price target current level reiter buy rate
page analyst certif import disclosur
develop insulin infus system peopl insulin-depend diabet
compani omnipod system novel dispos patch pump believ offer
varieti advantag tradit durabl insulin pump includ elimin
tube connect pump patient improv comfort increas conveni
attribut allow carv meaning posit insulin pump
market estim top world-wide revenu last year
believ compani continu take share go forward driven recent
competitor exit market launch new dash mobil platform shift
direct sale europ label expans includ concentr insulin formul
estim could effect doubl omnipod address market open
type opportun take factor account see
posit sustain top line growth next year view
growth outlook least partial reflect stock current level believ
continu execut steadi cadenc pipelin oper catalyst next
month scarciti compar growth stori across small-cap
med-tech univers drive continu out-performance
valu primarili ev/sal basi use repres group small-to-
mid cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim group current trade
ntm sale bracket insulet multipl lower price
target base previous multipl forward
ntm sale estim signific upsid potenti target current level
downsid risk rate price target includ failur keep pace
innov competitor caus omnipod adopt fall short street
expect disrupt compani product suppli chain faster
anticip penetr neulasta biosimilar could neg impact
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
